Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Annual Information Update

7 Jul 2006 16:55

Celsis International PLC07 July 2006 CELSIS INTERNATIONAL PLC ANNUAL INFORMATION UPDATE 7 July 2006: Celsis International plc, the rapid diagnostics and analyticalservices company, is pleased to provide an annual information update, inaccordance with the requirements of the Prospectus Rule 5.2. This update refersto information that has been published or made available by the Company to thepublic over the twelve months ended 7 July 2006. 1. Announcements made via a Regulatory Information Service The following regulatory announcements have been made by the Company via aRegulatory Information Service during the previous 12 months. Date of Publication Regulatory Headline 16 June 2006 Doc re: Acquisition14 June 2006 Acquisition14 June 2006 Final Results6 June 2006 Notice of Results28 March 2006 Trading Statement10 March 2006 Treasury Stock7 March 2006 Holding(s) in Company7 March 2006 Holding(s) in Company3 February 2006 New Contracts1 February 2006 Holding(s) in Company30 January 2006 Holding(s) in Company14 November 2005 Change of Adviser9 November 2005 Holding(s) in Company8 November 2005 Interim Results5 October 2005 Notice of Results29 September 2005 Trading Statement22 September 2005 Treasury Stock22 September 2005 Re Agreement21 September 2005 Director/PDMR Shareholding30 August 2005 Share Consolidation24 August 2005 Blocklisting Interim Review4 August 2005 Director/PDMR Shareholding26 July 2005 Result of AGM26 July 2005 AGM Statement18 July 2005 Dividend Declaration11 July 2005 Holding(s) in Company Details of all regulatory announcements for the Company can be found on theLondon Stock Exchange website at: www.londonstockexchange.com 2. Documents filed with Companies House The following documents have been filed by the Company with the Registrar ofCompanies at Companies House during the previous 12 months. Date Document type Description 22 June 2006 403a Declaration of mortgage/charge14 September 2005 288c Change in Director and secretary's particulars23 August 2005 AA Report & accounts01 August 2005 288c Change in Director's particulars11 July 2005 363s Returns Copies of documents filed at Companies House can be obtained from CompaniesHouse, Crown Way, Cardiff, CF14 3UZ or if you are a registered user, throughCompanies House Direct at www.direct.companieshouse.gov.uk. 3. Documents filed with the Financial Services Authority The following documents have been filed by the Company with the FinancialServices Authority and/or sent to shareholders during the previous 12 months. Date Description 3 July 2006 2006 Annual Report and Accounts3 July 2006 Circular for Company Share Option Plan14 June 2006 Circular for the Proposed Acquisition of In Vitro Technologies Inc Copies of the above documents may be viewed at the UK Listing Authority'sDocument Viewing Facility at 25 the North Colonnade, Canary Wharf, London E145HS. Enquiries: Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Ben AtwellAnna Keeble Notes to editors Celsis International plc Celsis International plc is a rapid diagnostics and analytical services company. The company is listed on the London Stock Exchange (CEL.L). Using proprietary technology, the Product Group is the world leader in theprovision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical and biopharmaceuticalcompanies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.